ClinicalTrials.gg
RecruitingNCT07654257SASHAUpdated Oct 23, 2026

Single FrAction Interstitial BreaSt BracHytherApy

A Phase 2 interventional study of Partial Breast Irradiation in Breast Cancer, sponsored by Virginia Commonwealth University. Recruiting at 1 site in United States. Open to female participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Virginia Commonwealth University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 23, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
134
Allocation
Not applicable
Ages
40 Years to 85 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Breast Neoplasms by Virginia Commonwealth University — 5 open to participants now, 8 under way, none of them phase 3. Breast Neoplasms · Virginia Commonwealth University.

Planned enrollment
7th of 23
134 · median 46
Started
2026
with 2 others
Phase 2
8 of 26
3 open now
Registered
25th of 26
by date

Among the 26 studies in Breast Neoplasms by Virginia Commonwealth University, this one is the 7th largest by planned enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2026, is one of 8 in phase 2, and was the 25th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

5 of the 26 studies in Breast Neoplasms by Virginia Commonwealth University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 40 Years to 85 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Breast Neoplasms by Virginia Commonwealth University, or all of them as a file.
02

Study summary

This phase 2, single arm prospective study has been designed to determine the safety of delivering accelerated partial breast irradiation (APBI) with a multicatheter interstitial implant in a single fraction over 1 day. This is a method of delivering radiation therapy directly into or close to a tumor.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Breast Cancer
  • Radiation
04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female
  • New diagnosis of Ductal Carcinoma in Situ (DCIS) and/or invasive breast carcinoma per histologic evaluation
  • Age 40-85 at diagnosis
  • Previous lumpectomy with surgical margins histologically free of invasive tumor and DCIS as determined by the pathologist
  • T stage of Tis, T1, or T2
  • T2 tumors must be ≤3 cm in maximum diameter
  • If the tumor is human epidermal growth factor receptor ()-positive, the patient is planning to receive or has already received HER2-directed therapy
  • For patients with invasive breast cancer, an axillary staging procedure must be performed (either sentinel node alone or axillary dissection [with a minimum of 6 axillary nodes removed]) and the axillary node(s) must be pathologically negative Note: N0(i+) is not an exclusion criterion

Note: Patients meeting all of the following criteria are not required to undergo the axillary staging procedure:

  • ≥70 years of age
  • Estrogen receptor (ER)+, progesterone receptor (PR)+/-, HER2-
  • Grade 1-2 breast cancer
  • Tumor ≤2 cm in size

Note: If patients meet all the following criteria, the decision to avoid sentinel lymph node biopsy can be at the discretion of the breast surgeon:

  • 50-69 years of age
  • Grade 1-2 breast cancer
  • Clinically negative axilla by ultrasound and/or magnetic resonance imaging (MRI)
  • ER+, PR+, HER2-
  • Tumor ≤2 cm in size
  • Agrees to comply with aromatase inhibitor recommendation
  • Ability to begin brachytherapy within 12 weeks following lumpectomy, re- excision of margins, or completion of chemotherapy
  • Ability to understand and the willingness to sign a written document

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding
  • Active collagen-vascular disease
  • Paget's disease of the breast
  • Any prior history of DCIS or invasive breast cancer prior to the current diagnosis
  • Any prior history of breast radiation therapy (RT) or thoracic RT for any condition
  • Multicentric carcinoma (DCIS or invasive)
  • Synchronous bilateral invasive or non-invasive breast cancer
  • Surgical margins that cannot be microscopically assessed or that are positive
  • Treatment with chemotherapy
  • Excision cavity that cannot be clearly delineated or is not amenable to implant per the treating investigator
  • Medical, psychological, or social condition that, in the opinion of the investigator, may increase the patient's risk or limit the patient's adherence with study requirements
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
134 participants (estimated)

Study arms

  • Experimental
    Partial Breast Irradiation

    Brachytherapy delivered with multiple interstitial catheters, given in a single fraction over 1 day

    Drug: Partial Breast Irradiation

Interventions

  • DrugPartial Breast Irradiation

    16 Gy × 1 fraction via multicatheter brachytherapy delivered over 1 day

    Also known as: Brachytherapy

06

What researchers measure

Primary outcomes

  1. Assess and compare the toxicity of a 1-day course of accelerated partial breast irradiation (APBI) to that of clinical trials: NSABP-B-39 (NCT00103181), RTOG-0413, TRIUMPH-T (NCT02526498), and ASHBY (NCT06185205)

    Incidence of accelerated partial breast irradiation (APBI) related toxicities of interest occurring at grade ≥3 at 1, 3, and 5 years after APBI. The descriptions and grading scales found in the The National Cancer Institutes' (NCI) Common Terminology Criteria for Adverse Events is a descriptive terminology (CTCAE), a list of standardized definitions for adverse events, revised v6.0 will be utilized for adverse (AE) (toxicity) reporting.

    Time frame: Baseline through 30 days following treatment, up to 5 years.

Secondary outcomes

  1. Assess the rate of excellent or good cosmesis at 1, 3, and 5 years after a 1-day course of APBI utilizing the Breast Cancer Treatment Outcome Scale (BCTOS-12)

    Cosmetic results at 1, 3, and 5 years after APBI, as assessed by The Breast Cancer Treatment Outcome Scale (BCTOS-12), a shortened, validated patient-reported outcome measure designed to assess aesthetic and functional outcomes after breast-conserving surgery. This is scored on a scale of 1-4 ("no difference" to "large difference"), where lower scores indicate better outcomes of satisfaction

    Time frame: Baseline, 6 months, 1 year, 3 years, up to 5 years following treatment

  2. Assess the rate of excellent or good cosmesis at 1, 3, and 5 years after a 1-day course of APBI utilizing the breast cancer core checklist (postoperative) (BREAST-Q)

    The BREAST-Q radiation-specific module patient-reported outcome measure (PROM) that evaluates patient satisfaction with the cosmetic effects of radiation The Breast-Q is 6 questions and scored on a scale of 1-3 ("not at all" to "a lot") with lower scores indicating better outcomes of satisfaction.

    Time frame: Baseline, 6 months, 1 year, 3 years, up to 5 years following treatment

  3. Assess the rate of excellent or good cosmesis after a 1-day course of APBI utilizing the Harvard Cosmesis Scale

    The Harvard Cosmesis Scale is a physician-rated form will be used by the radiation oncologist to score cosmesis with the following criteria: * Excellent: treated breast looks essentially the same as the contralateral breast as it relates to radiation effects. This includes patients with grade 1 punctate scarring. * Good: minimal but identifiable radiation effects of the treated breast. This includes patients with grade 2 punctate scarring. * Fair: significant radiation effects readily observable. * Poor: severe sequelae of breast tissue secondary to radiation effect.

    Time frame: Baseline, 6 months, then annually up to 5 years following treatment

  4. Assess the rate of excellent or good cosmesis at 1, 3, and 5 years after a 1-day course of APBI assessed by Digital Photographs

    Digital photographs will be taken to visualize any potential changes in breast shape or contour. These will be taken by study staff utilizing the Radiation Oncology Department's designated camera. blindly analyzed by 2-3 radiation oncologists using the following 4-point numerical scale: * 4 (Excellent): the treated breast looks essentially the same as the contralateral breast as it relates to radiation effects. This includes patients with grade 1 punctate scarring. * 3 (Good): minimal but identifiable radiation effects of the treated breast. This includes patients with grade 2 punctate scarring. * 2 (Fair): significant radiation effects readily observable. * 1 (Poor): severe sequelae of breast tissue secondary to radiation effect. Photos will be uploaded to the digital study record. Analysis will be batched as study progresses. Each individual score as well as the average score will be entered into the electronic case report form (eCRF).

    Time frame: Baseline, 5 weeks, 6 months, annually up to 5 years following treatment

  5. Assess cumulative treatment-related breast toxicities for up to 5 years after a 1-day course of accelerated partial breast irradiation (APBI)

    Incidence of treatment-related breast toxicities of interest occurring at any grade within 5 years after APBI. Toxicities will be graded using the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 6.

    Time frame: Baseline, up to 5 years following treatment

  6. Determine the percentage of patients who remain free of local disease progression (e.g., tumor recurrence or local spread) of breast cancer when treated with a 1-day course of APBI

    Disease control will be assessed by physical examination and mammography. All cases of local failure must be confirmed using pathologic criteria established by Recht et al will be used to help classify the type of local in-breast recurrence as follows: * True Recurrence/Marginal Miss (TR/MM) Failure: a recurrence of the treated cancer within or immediately adjacent to the primary tumor site. * Elsewhere (E) Failure: local recurrence several centimeters from the primary site and is generally believed to be a new primary cancer. Classification of the failure type is at the discretion of the treating investigator.

    Time frame: 1 year, 3 years, and up to 5 years following treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Oct 2036, 120 months after the start.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 120 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: start Sep 2026 → Oct 2026, primary completion Sep 2036 → Oct 2036 and completion Sep 2036 → Oct 2036.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2026
First posted
Jun 17, 2026
StartActual
Oct 19, 2026was Sep 2026
Primary completionEst.
Oct 31, 2036was Sep 2036
CompletionEst.
Oct 31, 2036was Sep 2036
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 23, 2026
Sites
Virginia Commonwealth University is now Recruiting
Oct 23, 2026
Start date
Sep 1, 2026→Oct 19, 2026 (actual)
Oct 23, 2026
Primary completion
Sep 30, 2036→Oct 31, 2036
Oct 23, 2026
Study completion
Sep 30, 2036→Oct 31, 2036
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Not yet recruiting→Recruiting
    Virginia Commonwealth University is now Recruiting
    Start date Sep 1, 2026→Oct 19, 2026 (now actual)
    Primary completion Sep 30, 2036→Oct 31, 2036
    Study completion Sep 30, 2036→Oct 31, 2036
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07654257
Responsible party
Sponsor
First posted
Jun 17, 2026
Start date
Oct 19, 2026
Primary completion
Oct 31, 2036 (estimated)
Completion
Oct 31, 2036 (estimated)
Last update
Oct 23, 2026

Study contacts

Massey IIT Research Operations
Contact
masseyepd@vcu.edu
804-628-6430
Bridget Quinn, MD
principal investigator · Virginia Commonwealth University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion